Benitec Biopharma (BNTC) announced Tuesday morning that the European Commission has granted Orphan Drug Designation to BB-301 for the treatment of patients with oculopharyngeal muscular dystrophy.
from RTT - Before the Bell http://ift.tt/2jnfOw8
via IFTTT
No comments:
Post a Comment